Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Nintedanib Action Pathway
Homo sapiens
Drug Action Pathway
Nintedanib is a versatile triple angiokinase inhibitor used in the treatment of several conditions. It's indicated for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease, and chronic fibrosing interstitial lung diseases with a progressive phenotype, where it helps slow down the decline in pulmonary function. Additionally, in combination with docetaxel, nintedanib is employed for non-small cell lung cancer (NSCLC) treatment, specifically for patients who have not responded to first-line chemotherapy options. This drug offers valuable therapeutic options for these challenging medical conditions.
References
Nintedanib Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Gerald J. Roth, Armin Heckel, Florian Colbatzky, Sandra Handschuh, Jörg Kley, Thorsten Lehmann-Lintz, Ralf Lotz, Ulrike Tontsch-Grunt, Rainer Walter, and Frank Hilberg Journal of Medicinal Chemistry 2009 52 (14), 4466-4480 DOI: 10.1021/jm900431g
Keating GM: Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs. 2015 Jul;75(10):1131-40. doi: 10.1007/s40265-015-0418-6
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings